Alvotech, Advanz Pharma File AVT29 Line Extension To Mynzepli Marketing Authorization With EMA For Proposed Eylea 8mg Biosimilar
Share
Why It Matters
Alvotech and Advanz Pharma filed paperwork with Europe's medicine authority. They want to sell a new stronger version of their eye drug copy.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.